Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 29, 2024, serves as a report of a foreign private issuer for the month of March 2024. The filing primarily furnishes the audited consolidated financial statements of Enlivex Therapeutics Ltd. for the fiscal years ended December 31, 2023, and 2022, as well as the three-year period ended December 31, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the audited consolidated financial statements provided as Exhibit 99.1, which are incorporated by reference into the registrant's registration statements on Forms S-8, F-3, and F-3MEF.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It references the inclusion of financial statements for the years ended December 31, 2023, and 2022, allowing for comparison, but does not summarize the variances within the body of this report.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or disclosures regarding contingencies and unusual items. The document functions as a vehicle to deliver the audited financial statements to the SEC.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific audited financial figures for the years ended December 31, 2023, and 2022.
- Verify the incorporation of these statements into the referenced registration statements (File Nos. 333-256799, 333-232413, 333-232009, 333-252926, and 333-264561).
- Confirm the audit opinion provided by Yarel + Partners (Exhibit 99.2).
- Check for any subsequent filings that may provide interim results for the period following December 31, 2023.